Homepage Top Section2

In-licensed from Asceneuron, this new molecular entity is currently undergoing a Phase II trial. The trial aims to assess the therapy’s efficacy, pharmacokinetics, and safety in adults diagnosed

This status signifies the potential of the gel to broaden its therapeutic applications in chronic wound healing, accelerating its availability to patients. SolasCure noted that this hydrogel releases

This collaboration is expected to strengthen the country’s role as an international hub for drug discovery. This new support is part of several programmes under the Medical Innovation

PiaSky will be given as the first monthly subcutaneous therapy for adults and adolescents aged 13 years or more with a minimum body weight of 40kg. Patients have

The partnership grants Daewoong access to Salipro’s expertise and platform specifically designed for stabilising challenging membrane proteins such as G protein-coupled receptors (GPCRs), ion channels, and transporters. The

MRT-8102 is a NEK7-directed molecular glue degrader being developed to treat inflammatory diseases driven by the NLRP3 inflammasome and IL-1β. Monte Rosa Therapeutics CEO Markus Warmuth said: “The

Under the agreement, Neowise will be eligible for an upfront payment and will also receive future milestone payments. These payments are contingent upon reaching specific development, regulatory, and

Duvyzat must be administered alongside corticosteroids and is not limited by the patient’s specific genetic mutation. The decision is applicable across all 27 EU member states, as well

The alliance leverages both companies’ experience in the field of biosimilars. By combining their resources, they aim to expedite the development process while expanding the product’s availability worldwide.